专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

2. 发明申请

WO2007050318A3 LIPIDOMICS APPROACHES FOR CENTRAL NERVOUS SYSTEM DISORDERS 审中-公开
标题翻译：用于中枢神经系统疾病的脂肪代谢方法
公开(公告)号：WO2007050318A3
公开(公告)日：2007-09-07
申请号：PCT/US2006040026
申请日：2006-10-12
申请人： UNIV DUKE , LIPOMICS TECHNOLOGIES INC , KADDURAH-DAOUK RIMA F , KRISHNAN K RANGA RAMA , MCEVOY JOSEPH P , BAILLIE REBECCA ANN
发明人： KADDURAH-DAOUK RIMA F , KRISHNAN K RANGA RAMA , MCEVOY JOSEPH P , BAILLIE REBECCA ANN
IPC分类号： G01N33/92
CPC分类号： G01N33/92 , G01N2405/00 , G01N2405/04 , G01N2800/30 , G01N2800/302
摘要： The present invention has utilized the power of lipidomics to profile lipid metabolites and to characterize changes in lipid metabolism as they relate to CNS disorders. Lipidomic signatures can guide the development of diagnostic, prognostic and surrogate markers for CNS disorders; identification of new targets for drug design based on highlighted perturbed pathways; stratify patients with CNS disorders as to which pathways are impaired, and facilitate the determination of which patients with CNS disorders are candidates for a particular therapy, i.e. provide the tools for a personalized approach to therapy; identify which patients are responding or are developing side effects to a treatment; design of modified antipsychotics that have less metabolic side effects and enhanced activity; overcome the lag phase in response to some treatments; and find better combination therapies for CNS disorders that target the pathways that are impaired (e.g., impairments in lipid and/or carbohydrate metabolism).
摘要翻译：本发明利用脂质组学的功能来分析脂质代谢物并描述它们与CNS疾病相关的脂质代谢变化。脂质体标记可以指导中枢神经系统疾病的诊断，预后和替代标志物的发展; 基于突出的扰动途径确定药物设计的新目标; 分层中枢神经系统疾病患者，哪些途径受损，并有助于确定哪些中枢神经系统疾病患者是特定治疗的候选者，即为个体化治疗方法提供工具; 确定哪些患者正在应对或正在对治疗产生副作用; 具有较少代谢副作用和增强活性的改良抗精神病药的设计; 克服一些治疗响应的滞后期; 并找到针对受损途径（例如脂质和/或碳水化合物代谢障碍）的CNS疾病的更好的组合疗法。

3. 发明申请

WO2021016551A1 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
公开(公告)号：WO2021016551A1
公开(公告)日：2021-01-28
申请号：PCT/US2020/043473
申请日：2020-07-24
申请人： DUKE UNIVERSITY , OXFORD UNIVERSITY , ERASMUS MEDICAL CENTER , INDIANA UNIVERSITY SCHOOL OF MEDICINE , UNIVERSITY OF TEXAS , KADDURAH-DAOUK, Rima, F. , MAHMOUDIANDEHKORDI, Siamak , VAN DUIJIN, Comelia , AHMAD, Shahzad , SAYKIN, Andrew, J. , NHO, Kwangsik , BAILLIE, Rebecca , HAN, Xianlin
发明人： KADDURAH-DAOUK, Rima, F. , MAHMOUDIANDEHKORDI, Siamak , VAN DUIJIN, Comelia , AHMAD, Shahzad , SAYKIN, Andrew, J. , NHO, Kwangsik , BAILLIE, Rebecca , HAN, Xianlin
IPC分类号： G01N33/68 , A61P25/28 , A61P25/00 , C07K14/00 , G01N33/48
摘要： Described herein are methods for identifying or diagnosing Alzheimer's disease or poor cognition in a subject or population of subjects by analyzing biomarkers. In one aspect, the biomarkers comprise liver function enzymes or metabolites including alanine aminotransferase (ALT), aspartate aminotransferase (AST), ratio of ALT to AST, alkaline phosphatase, albumin, bilirubin, cholesterol and cholesterol metabolites, amino acids, phospholipids, bile acids,, or other metabolites. In another aspect, the biomarkers comprise alanine aminotransferase (ALT), aspartate aminotransferase (AST), or the ratio of ALT to AST levels. In another aspect, the marker comprises the genotype of the ALT or AST enzymes.

4. 发明申请

WO2018049268A1 BIOMARKERS FOR THE DIAGNOSIS AND CHARACTERIZATION OF ALZHEIMER'S DISEASE 审中-公开
标题翻译：生物标志物用于阿尔茨海默病的诊断和表征
公开(公告)号：WO2018049268A1
公开(公告)日：2018-03-15
申请号：PCT/US2017/050831
申请日：2017-09-08
申请人： DUKE UNIVERSITY , UNIVERSITY OF PENNSYLVANIA , HOUSTON METHODIST HOSPITAL , HELMHOLTZ ZENTRUM MUNCHEN , GERMAN CENTER FOR DIABETES RESEARCH (DZD) , ROSA & CO LLC , SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE , INDIANA UNIVERSITY SCHOOL OF MEDICINE , BIOCRATES LIFE SCIENCES AG , TOLEDO, Jon, B. , ARNOLD, Matthias , KASTEMULLER, Gabi , BAILLIE, Rebecca, A. , HAN, Xianlin , THOMPSON, Will , ST. JOHN-WILLIAMS, Lisa , KOAL, Therese , NHO, Kwangsik , MOSELEY, M., Arthur , SAYKIN, Andrew, J. , DORAISWAMY, Pudugramam, Murali
发明人： TOLEDO, Jon, B. , ARNOLD, Matthias , KASTEMULLER, Gabi , BAILLIE, Rebecca, A. , HAN, Xianlin , THOMPSON, Will , ST. JOHN-WILLIAMS, Lisa , KOAL, Therese , MOSELEY, M., Arthur , SAYKIN, Andrew, J. , DORAISWAMY, Pudugramam, Murali
IPC分类号： G01N33/50 , A61K31/661 , G01N33/92
摘要： Embodiments of the present disclosure relate generally to the analysis and identification of global metabolic changes in Alzheimer's disease (AD). More particularly, the present disclosure provides materials and methods relating to the use of metabolornics as a biochemical approach to identify peripheral metabolic changes in AD patients and correlate them to cerebrospinal fluid pathology markers, imaging features, and cognitive performance. Defining metabolic changes during AD disease trajectory and their relationship to clinical phenotypes provides a powerful roadmap for drug and biomarker discovery.
摘要翻译：本公开的实施方案一般涉及阿尔茨海默病（AD）中全局代谢变化的分析和鉴定。更具体地说，本公开提供了与使用代谢物作为生化方法相关的材料和方法，以鉴定AD患者中的外周代谢变化并将它们与脑脊液流体病理学标记，成像特征和认知表现相关联。定义AD疾病过程中的代谢变化及其与临床表型的关系为药物和生物标志物的发现提供了强有力的路线图。

5. 发明申请

WO2007127192A2 LIPIDOMIC APPROACHES TO DETERMINING DRUG RESPONSE PHENOTYPES IN CARDIOVASCULAR DISEASE 审中-公开
标题翻译：脂质体法在心血管疾病中确定药物反应表型
公开(公告)号：WO2007127192A2
公开(公告)日：2007-11-08
申请号：PCT/US2007009916
申请日：2007-04-24
申请人： UNIV DUKE , CHILDREN S HOSPITAL OAKLAND RE , LIPOMICS TECHNOLOGIES INC , MAYO CLINIC COLLEGE OF MEDICIN , KADDURAH-DAOUK RIMA , WIEST MICHELLE M , WATKINS STEVEN M , BAILLIE REBECCA A , PATNAIK MEETA , KRISHNAN K RANGA RAMA , WEINSHILBOUM RICHARD M , KRAUSS RONALD M
发明人： KADDURAH-DAOUK RIMA , WIEST MICHELLE M , WATKINS STEVEN M , BAILLIE REBECCA A , PATNAIK MEETA , KRISHNAN K RANGA RAMA , WEINSHILBOUM RICHARD M , KRAUSS RONALD M
IPC分类号： B29C71/02
CPC分类号： G01N33/92
摘要： The present invention concerns the application of lipidomics to statin treatment for disorders such as cardiovascular disorders. Hence, the invention provides, among other things, a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject following commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The invention further provides a method of correlating a lipid profile with a positive or negative response to a statin treatment regimen by obtaining a lipid profile of a sample from a mammalian subject before commencement of the treatment regimen; and correlating the lipid profile in the sample with a positive or negative response to the treatment regimen. The use of a means of detecting a lipid profile in a biological sample of a subject in determining if the subject is responding or will respond positively or negatively to a statin treatment regimen is also described.
摘要翻译：本发明涉及脂质组学应用于他汀类药物治疗诸如心血管疾病的疾病。因此，本发明尤其提供了一种方法，其通过在治疗方案开始后获得来自哺乳动物受试者的样品的脂质特征，将脂质特征与他汀类药物治疗方案的阳性或阴性反应相关联; 并将样品中的脂质分布与治疗方案的阳性或阴性反应相关联。本发明进一步提供了通过在治疗方案开始之前获得来自哺乳动物受试者的样品的脂质特征来将脂质特征与他汀类治疗方案的阳性或阴性反应相关联的方法; 并将样品中的脂质分布与治疗方案的阳性或阴性反应相关联。还描述了使用检测受试者的生物样品中的脂质特征的手段来确定受试者是否正在响应或将对他汀类药物治疗方案产生积极或消极响应。

6. 发明申请

WO2003078574A3 NOVEL METABOLIC TARGETS AND MARKERS 审中-公开
公开(公告)号：WO2003078574A3
公开(公告)日：2003-09-25
申请号：PCT/US2003/007242
申请日：2003-03-07
申请人： LIPOMICS TECHNOLOGIES, INC. , WATKINS, Steven, M. , BAILLIE, Rebecca, A.
发明人： WATKINS, Steven, M. , BAILLIE, Rebecca, A.
IPC分类号： A61K35/12
摘要： The present invention provides metabolic markers and targets, especially PEMT activity and metabolic markers and components associated therewith useful for diagnosing and treating various disease conditions.

7. 发明申请

WO2022081350A2 METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES 审中-公开
公开(公告)号：WO2022081350A2
公开(公告)日：2022-04-21
申请号：PCT/US2021/052863
申请日：2021-09-30
申请人： DUKE UNIVERSITY , KADDURAH-DAOUK, Rima, F. , KRISHNAN, Ranga, Rama , ARNOLD, Matthias , BAILLIE, Rebecca , HAN, Xianlin
发明人： KADDURAH-DAOUK, Rima, F. , KRISHNAN, Ranga, Rama , ARNOLD, Matthias , BAILLIE, Rebecca , HAN, Xianlin
IPC分类号： G16B20/00 , G01N33/53 , A61K38/43 , G01N33/50
摘要： Described herein are methods for identifying mitochondrial defects using metabolomics and genetic analyses and using this information to stratify patients and to correct for metabolic defects in a precision medicine approach. One embodiment is a method for isolating and analyzing samples containing one or more mitochondrial biomarker metabolites or genetic markers useful for the analysis, identification, stratification or classification, and treatment of metabolic changes associated with a CNS or neuropsychiatric disease in a subject and therapies useful for the treatment thereof. In one aspect, the biomarker metabolites comprise mitochondrial metabolites including acylcarnitines and endocannabinoids and the genetic analyses focus on metabolic enzymes or transport mechanisms.

8. 发明申请

WO2007050318A2 LIPIDOMICS APPROACHES FOR CENTRAL NERVOUS SYSTEM DISORDERS 审中-公开
标题翻译：脂质体学方法治疗中枢神经系统疾病
公开(公告)号：WO2007050318A2
公开(公告)日：2007-05-03
申请号：PCT/US2006/040026
申请日：2006-10-12
申请人： DUKE UNIVERSITY , LIPOMICS TECHNOLOGIES, INC. , KADDURAH-DAOUK, Rima F. , KRISHNAN, K. Ranga Rama , MCEVOY, Joseph P. , BAILLIE, Rebecca Ann
发明人： KADDURAH-DAOUK, Rima F. , KRISHNAN, K. Ranga Rama , MCEVOY, Joseph P. , BAILLIE, Rebecca Ann
IPC分类号： G01N33/487
CPC分类号： G01N33/92 , G01N2405/00 , G01N2405/04 , G01N2800/30 , G01N2800/302
摘要： The present invention has utilized the power of lipidomics to profile lipid metabolites and to characterize changes in lipid metabolism as they relate to CNS disorders. Lipidomic signatures can guide the development of diagnostic, prognostic and surrogate markers for CNS disorders; identification of new targets for drug design based on highlighted perturbed pathways; stratify patients with CNS disorders as to which pathways are impaired, and facilitate the determination of which patients with CNS disorders are candidates for a particular therapy, i.e. provide the tools for a personalized approach to therapy; identify which patients are responding or are developing side effects to a treatment; design of modified antipsychotics that have less metabolic side effects and enhanced activity; overcome the lag phase in response to some treatments; and find better combination therapies for CNS disorders that target the pathways that are impaired (e.g., impairments in lipid and/or carbohydrate metabolism).
摘要翻译：本发明利用脂质组学的力量来描绘脂质代谢物并鉴定与CNS疾病有关的脂质代谢变化。脂质体特征可以指导中枢神经系统疾病的诊断，预后和替代指标的发展; 根据突出的干扰途径确定药物设计的新目标; 将患有CNS病症的患者分层以确定哪些通路受损，并且有助于确定哪些患有CNS病症的患者是特定疗法的候选人，即为个体化治疗方法提供工具; 确定哪些患者对治疗有反应或正在产生副作用; 设计具有较少代谢副作用和增强活性的改良抗精神病药; 克服滞后阶段以回应一些治疗; 并寻找针对受损途径（例如，脂质和/或碳水化合物代谢障碍）的CNS障碍的更好的组合疗法。

9. 发明申请

WO2003078574A2 NOVEL METABOLIC TARGETS AND MARKERS 审中-公开
标题翻译：新的代表性目标和标记
公开(公告)号：WO2003078574A2
公开(公告)日：2003-09-25
申请号：PCT/US2003/007242
申请日：2003-03-07
申请人： LIPOMICS TECHNOLOGIES, INC. , WATKINS, Steven, M. , BAILLIE, Rebecca, A.
发明人： WATKINS, Steven, M. , BAILLIE, Rebecca, A.
IPC分类号： C12N
CPC分类号： G01N33/92 , A61K31/00 , A61K31/4415 , A61K31/455 , A61K31/51 , A61K31/519 , A61K31/7076 , A61K38/27 , C12N9/1003 , C12Y201/01017 , G01N33/57484 , G01N2800/52
摘要： The present invention provides metabolic markers and targets, especially PEMT activity and metabolic markers and components associated therewith useful for diagnosing and treating various disease conditions.
摘要翻译：本发明提供代谢标志物和靶标，特别是PEMT活性和与其相关的代谢标志物和组分，其可用于诊断和治疗各种疾病状况。

10. 发明申请

WO2021016551A8 COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE 审中-公开
公开(公告)号：WO2021016551A8
公开(公告)日：2021-01-28
申请号：PCT/US2020/043473
申请日：2020-07-24
申请人： DUKE UNIVERSITY , OXFORD UNIVERSITY , ERASMUS MEDICAL CENTER , INDIANA UNIVERSITY SCHOOL OF MEDICINE , UNIVERSITY OF TEXAS , KADDURAH-DAOUK, Rima, F. , MAHMOUDIANDEHKORDI, Siamak , VAN DUIJIN, Cornelia , AHMAD, Shahzad , SAYKIN, Andrew, J. , NHO, Kwangsik , BAILLIE, Rebecca , HAN, Xianlin
发明人： KADDURAH-DAOUK, Rima, F. , MAHMOUDIANDEHKORDI, Siamak , VAN DUIJIN, Cornelia , AHMAD, Shahzad , SAYKIN, Andrew, J. , NHO, Kwangsik , BAILLIE, Rebecca , HAN, Xianlin
IPC分类号： G01N33/68 , A61P25/28 , A61P25/00 , C07K14/00 , G01N33/48 , G01N2333/91188 , G01N2800/2814 , G01N2800/2821 , G01N2800/50 , G01N33/6896
摘要： Described herein are methods for identifying or diagnosing Alzheimer's disease or poor cognition in a subject or population of subjects by analyzing biomarkers. In one aspect, the biomarkers comprise liver function enzymes or metabolites including alanine aminotransferase (ALT), aspartate aminotransferase (AST), ratio of ALT to AST, alkaline phosphatase, albumin, bilirubin, cholesterol and cholesterol metabolites, amino acids, phospholipids, bile acids,, or other metabolites. In another aspect, the biomarkers comprise alanine aminotransferase (ALT), aspartate aminotransferase (AST), or the ratio of ALT to AST levels. In another aspect, the marker comprises the genotype of the ALT or AST enzymes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式